{"filing":{"accession_number":"0001815776-26-000051","cik":"0001815776","ticker":"LENZ","company_name":"LENZ Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"lenz-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/lenz-20260811.htm"},"events":[{"id":26943,"run_id":24507,"accession_number":"0001815776-26-000051","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"LENZ Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026. The disclosure includes Q2 2026 total revenue of $5.5 million (product sales of $1.7 million and license revenue of $3.8 million), net loss of $31.9 million for the quarter, and detailed operating metrics. The press release is attached as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings releases. This is material to investors as it reports the company's first full quarter of commercial product sales following VIZZ's FDA approval in July 2025.","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28248,"accession_number":"0001815776-26-000051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"LENZ Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026. The disclosure includes Q2 2026 total revenue of $5.5 million (product sales of $1.7 million and license revenue of $3.8 million), net loss of $31.9 million for the quarter, and detailed operating metrics. The press release is attached as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings releases. This is material to investors as it reports the company's first full quarter of commercial product sales following VIZZ's FDA approval in July 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:17:04.372160+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28248,"accession_number":"0001815776-26-000051","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"LENZ Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026. The disclosure includes Q2 2026 total revenue of $5.5 million (product sales of $1.7 million and license revenue of $3.8 million), net loss of $31.9 million for the quarter, and detailed operating metrics. The press release is attached as Exhibit 99.1 and is the core content of Item 2.02, which is the standard Item for earnings releases. This is material to investors as it reports the company's first full quarter of commercial product sales following VIZZ's FDA approval in July 2025.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:17:04.372160+00:00","company_name":"LENZ Therapeutics, Inc.","ticker":"LENZ","filing_date":"2026-08-11"}]}